Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL ANN ARBOR, Mich., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner for the development and commercialization of NEXLETOL® (bempedoic acid) tablets in Japan, has received approval from the Japanese Ministry of Health, Labour and Welfare to market NEXLETOL...
Space42 and Viasat to Launch Equatys Venture with Access to World’s Largest Coordinated Spectrum Block for Global Direct to Device Services Enables global delivery of D2D services wherever terrestrial networks are not availableCreates industry-first space tower company model, implementing shared space and ground Non-Terrestrial-Network (NTN) infrastructure, lowering capital costs and improving spectrum utilization for all participantsFacilitates evolution of existing Mobile Satellite Services to a 5G network environment PARIS, Sept. 15, 2025 (GLOBE NEWSWIRE) -- (ADX: SPACE42), the UAE-b...
Viasat Announces ViaSat-3 F2 Scheduled to Launch in October, Expected to More Than Double Viasat’s Bandwidth Capacity ViaSat-3 F2 dynamic beam forming capabilities will deliver extensive benefits to customers in the highest demand places, with anticipated service entry in early 2026 Viasat’s ultra-high-capacity constellation is designed to meet the increasing demand for resilient, global satellite communications from commercial mobility and defense customers CARLSBAD, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: VSAT), a global leader in satellite communications, tod...
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias – Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence – – Guideline Recognition of ‘Strike Early and Strike Strong’ Approach with Early Combination Lipid-Lowering Therapy Affirms Continued Development of Company’s Oral Triple Combination Therapies in U.S. – ANN ARBOR, Mich., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today welcomed the inclusion of bempedoic acid as the only n...
Esperion to Participate in Upcoming September Investor Conferences ANN ARBOR, Mich., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of September, which can be found on our investor relations . Cantor Global Healthcare Conference in New York on September 3, 2025, at 9:45 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8, 2025, at 2:00 p.m. ET. Live webcasts can be accessed on the investor and media section of the Esperio...
Australia and New Zealand Expand SouthPAN Program with Viasat through $252m AUD Award for Additional Satellite Services Geoscience Australia and Toitū Te Whenua Land Information New Zealand have expanded the agreement with Viasat for the world class satellite-based augmentation system, SouthPAN CARLSBAD, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Viasat, Inc. (NASDAQ: VSAT), a global leader in satellite communications, today announced a $252 million AUD award from Geoscience Australia (GA) and Toitū Te Whenua Land Information New Zealand (LINZ) to deliver additional satellite services fo...
Viasat Unveils HaloNet Capability Portfolio for Near-Earth Communications and Beyond Viasat’s modular portfolio of capabilities offers space-to-ground connectivity and relay solutions for resilient and responsive data transport CARLSBAD, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: VSAT), a global leader in satellite communications, today unveiled its HaloNet™ portfolio, a modular set of capabilities with a next-generation connectivity architecture that unifies space and terrestrial connectivity into a cohesive service offering. Developed across global teams within Viasat Governm...
A director at International Flavors & Fragrances Inc bought 15,450 shares at 64.802USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such indivi...
Viasat Releases First Quarter Fiscal Year 2026 Financial Results CARLSBAD, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: VSAT), a global leader in satellite communications, today published its first quarter fiscal year 2026 financial results in a letter to shareholders, which, along with webcast slides, is now posted to the section of Viasat’s website. As previously announced, Viasat will host a conference call today, Tuesday, August 5, 2025 at 2:30 p.m. Pacific Time / 5:30 p.m. Eastern Time. The dial in numbers for the conference are: (800) 715-9871 in the U.S. or +1 (646) 30...
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update – Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with Three ANDA Filers Not to Market Generic Versions of NEXLETOL® (bempedoic acid) Prior to 2040 – – First Quarter of Operating Income from Ongoing Business with Plans for Sustainable Profitability Starting in Q1 2026 – – Conference Call and Webcast Today at 8:00 a.m...
Viasat Comments on Letter from Carronade Capital Management CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Viasat, Inc. (NASDAQ:VSAT) (“Viasat” or “the Company”), a global leader in satellite communications, today issued the following statement in response to a letter from Carronade Capital Management. "Viasat consistently engages in dialogue with its shareholders and welcomes constructive input focused on maximizing shareholder value. As a leader in satellite infrastructure and connectivity, in-flight connectivity and critical military and government communication, Viasat is well-p...
Viasat Selected to Deliver Next-Generation Encryption for US Government Cloud Data Centers As a key provider to cloud data centers today, Viasat will develop a next-generation high-assurance, high-speed Ethernet Data Encryptor (EDE) for protecting classified data across government cloud data centers and transport networks CARLSBAD, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: VSAT), a global leader in satellite communications, today announced it was selected by the U.S. Government to build a next-generation Ethernet Data Encryptor (EDE) solution as part of a sole-source multi-mil...
Viasat Sets August 5, 2025 for First Quarter Fiscal Year 2026 Financial Results Conference Call and Webcast CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: VSAT), a global leader in satellite communications, today announced it will release its first quarter fiscal year 2026 financial results on Tuesday, August 5, 2025 after the market closes, via a letter to shareholders posted to the section of its website. The Company will also host a conference call and webcast on Tuesday, August 5, 2025 at 2:30 p.m. Pacific Time / 5:30 p.m. Eastern Time. To participate on the live conf...
Esperion to Report Second Quarter 2025 Financial Results on August 5 ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after completion of the call and...
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 ANN ARBOR, Mich., July 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Accord Healthcare Inc. This agreement resolves the patent litigation brought by Esperion against Accord Healthcare Inc. in response to Accord Healthcare Inc’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.